• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Pyxis Oncology Inc.

    4/29/25 7:43:26 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PYXS alert in real time by email
    DEFA14A 1 2025proxy_defa14a.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

    SCHEDULE 14A

    (Rule 14a-101)

    INFORMATION REQUIRED IN PROXY STATEMENT

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    Filed by the Registrant ☒

    ​

    ​

    Filed by a Party other than the Registrant  ☐

    Check the appropriate box:

    5 ☐

    ​

    ​

    Preliminary Proxy Statement

     ☐

    ​

    ​

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    ​

    ​

    Definitive Proxy Statement

     ☒

    ​

    ​

    Definitive Additional Materials

     ☐

    ​

    ​

    Soliciting Material under § 240.14a-12

     

    PYXIS ONCOLOGY, INC.

    (Name of Registrant as Specified in its Charter)

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    ☒

    ​

    ​

    No fee required.

     ☐

    ​

    ​

    Fee paid previously with preliminary materials.

     ☐

    ​

    ​

    Fee computed on table in exhibit required per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     


    img21784560_0.jpg

     

    PYXIS ONCOLOGY P.O. Box 8016, CARY, NC 27512-9903 YOUR VOTE MATTERS! Scan QR for digital voting Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 11, 2024 For stockholders of record as of April 18, 2024 To order paper materials, use one of the following methods. INTERNET: www.investorelections.com/ Call 1-866-648-8133 [email protected] * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. Pyxis Oncology, Inc. Annual Meeting of Stockholders Tuesday, June 11, 2024 10:00 AM, Eastern Time Annual Meeting to be held live via the internet - please visit at www.proxydocs.com/PYXS for more details. You must register to attend the meeting online and/or participate at www.proxydocs.com/PYXS For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/PYXS To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 31, 2024. SEE REVERSE FOR FULL AGENDA Copyright © 2024 BetaNXT, Inc. or its affiliates. All Rights Reserved


    img21784560_1.jpg

    THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1 AND 2 Pyxis Oncology, Inc. Annual Meeting of Stockholders 1. The election of one Class I director and three Class III directors named in the proxy statement 1.01 Santhosh Palani, Ph.D., CFA 1.02 John Flavin 1.03 Lara Sullivan,M.D. 1.04 Jakob Dupont,M.D. 2. The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December31, 2024 NOTE: The transaction of such other business as may properly come before the meeting, or any adjournment or postponement thereof.


    Get the next $PYXS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PYXS

    DatePrice TargetRatingAnalyst
    11/21/2024Outperform → Mkt Perform
    William Blair
    11/8/2024$13.00Overweight
    Stephens
    8/8/2024$10.00Buy
    Stifel
    5/7/2024$10.00Buy
    Jefferies
    2/9/2024$8.00Buy
    BTIG Research
    1/23/2024$12.00Outperform
    Leerink Partners
    9/5/2023$7.00Outperform
    RBC Capital Mkts
    11/2/2021$16.00Neutral
    B of A Securities
    More analyst ratings

    $PYXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Pyxis Oncology downgraded by William Blair

      William Blair downgraded Pyxis Oncology from Outperform to Mkt Perform

      11/21/24 7:55:42 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stephens initiated coverage on Pyxis Oncology with a new price target

      Stephens initiated coverage of Pyxis Oncology with a rating of Overweight and set a new price target of $13.00

      11/8/24 8:24:38 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Pyxis Oncology with a new price target

      Stifel initiated coverage of Pyxis Oncology with a rating of Buy and set a new price target of $10.00

      8/8/24 6:48:55 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by President ,CEO & CMO Sullivan Lara

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      4/2/25 9:06:50 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Metzger Michael A

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      4/2/25 9:05:43 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by SVP, Chief Accounting Officer Wadhane Jitendra

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      4/2/25 9:04:17 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Pyxis Oncology Inc.

      SC 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)

      11/12/24 11:53:51 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pyxis Oncology Inc.

      SC 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)

      11/6/24 4:36:24 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Pyxis Oncology Inc. (Amendment)

      SC 13D/A - Pyxis Oncology, Inc. (0001782223) (Subject)

      4/3/24 5:10:59 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PYXS
    Financials

    Live finance-specific insights

    See more

    $PYXS
    Leadership Updates

    Live Leadership Updates

    See more

    $PYXS
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $PYXS
    SEC Filings

    See more

    $PYXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024

      - Preliminary data from the first-in-patient Phase 1 dose escalation trial of PYX-201 to be announced at upcoming virtual and in-person event in New York City on Wednesday, November 20, 2024, at 4:30 p.m. ET - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash runway into 2H 2026 BOSTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. The Company ended the third quarter of 20

      11/12/24 7:30:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

      - Preliminary data from the Phase 1 trial of PYX-201 remains on track to be announced in the fall of 2024 - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash runway into 2H 2026 BOSTON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. The Company ended the second quarter of 2024 with $157.2 million in cash, cash equivalents, restricted cash and short-term investments, which is expected

      8/14/24 4:05:00 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

      PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice President, Chief Business Officer PYX-106 Phase 1 trial clinical readout on track for 2H 2024 Expected cash runway into 2H 2026 BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. PYX-201, a first-in-concept tumor stroma targeting antibody-drug conjugate (ADC) against the stromal Extradom

      5/14/24 7:30:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

      BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) since 2015. "We are delighted to have Michael, a proven leader in our industry with a robust track record of success, join the board," said Lara S. Sullivan, M.D., President and Chief Ex

      6/10/24 7:30:00 AM ET
      $PYXS
      $SNDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

      BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors, effective March 12, 2024. "We are thrilled to have Santhosh join the Pyxis Oncology board. Santhosh brings a wealth of business, investment, strategic, and board experience to our team," said Lara S. Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology. "Santhosh's guidance, drawing from his experience working across the biopharma industry, will be invaluable as we continue clinical devel

      3/13/24 8:00:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 1910 Genetics Appoints Dr. Shaan C. Gandhi as Independent Board Director

      Dr. Gandhi is VP and Head of Strategic Partnerships for Pfizer Ignite and will bring clinical, strategic and financial leadership to biotech's board 1910 Genetics, the only biotech advancing small and large molecule drug discovery with an automated, multimodal AI platform, today announced the appointment of Shaan C. Gandhi, MD, DPhil, to its board of directors. Gandhi joins as an independent board director and will provide a critical clinical perspective alongside his extensive background in biotechnology investing and strategic collaboration at a time when 1910 Genetics continues to build pharmaceutical and technology partnerships and advance its own pipeline of AI-derived therapeutics.

      12/19/23 9:00:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

      - Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO, formerly PYX-201), driving anti-tumor activity via direct tumor killing, bystander effect and immunogenic cell death - On track to report preliminary data from Phase 1 monotherapy expansion cohorts of MICVO for 2L/3L R/M HNSCC patients who have received prior platinum-based chemotherapy and prior PD-(L)1 inhibitor therapy in second half of 2025, and 2L/3L R/M HNSCC patients who have received prior EGFRi and PD-1 inhibitor therapy in first half of 2026 - On track to report preliminary data from Phase 1 trial of MICVO in combination with pembrolizumab targeting mul

      5/15/25 7:00:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology to Participate in Two Upcoming Investor Conferences

      BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in fireside chats and be available for one-on-one meetings with investors at the following two upcoming investor conferences. 2025 RBC Capital Markets Global Healthcare Conference in New York, NY on Wednesday, May 21 at 2:05 p.m. ETJefferies Global Healthcare Conference in New York, NY on Thursday, June 5 at 4:55 p.m. ET A live webcast and replay of the fireside chats will be available on th

      5/14/25 7:30:00 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

      Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders Mouse analog of MICVO in a syngeneic model indicated strong activity of the cytotoxic Auristatin0101 payload and potential for MICVO monotherapy to drive immunogenic cell death, a key hypothesis for MICVO's mechanism Combination of a mouse analog of MICVO and anti-PD-1 therapy in a syngeneic model resulted in enhanced tumor clearance and longer immunological memory compared to either treatment alone Totality of pre-clinical data presented at AACR 2025 strongly support MICVO's uniqu

      4/25/25 1:17:47 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Pyxis Oncology Inc.

      10-Q - Pyxis Oncology, Inc. (0001782223) (Filer)

      5/15/25 7:41:51 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pyxis Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Pyxis Oncology, Inc. (0001782223) (Filer)

      5/15/25 7:35:33 AM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Pyxis Oncology Inc.

      SCHEDULE 13G/A - Pyxis Oncology, Inc. (0001782223) (Subject)

      5/6/25 4:17:33 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO & COO Connealy Pamela Ann bought $174,364 worth of shares (88,850 units at $1.96) (SEC Form 4)

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      11/27/24 5:09:59 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Connealy Pamela Ann bought $14,960 worth of shares (8,000 units at $1.87), increasing direct ownership by 0.99% to 818,532 units (SEC Form 4)

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      9/28/23 4:32:03 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wadhane Jitendra bought $4,675 worth of shares (2,500 units at $1.87), increasing direct ownership by 1% to 226,937 units (SEC Form 4)

      4 - Pyxis Oncology, Inc. (0001782223) (Issuer)

      9/27/23 6:37:45 PM ET
      $PYXS
      Biotechnology: Pharmaceutical Preparations
      Health Care